secwatch.observer — SEC 8-K summary
======================================

Issuer:     EBR Systems, Inc. (EBRCZ)
CIK:        0001347123
Form:       8-K
Filed at:   2025-04-14T23:59:59+00:00
Accession:  0001214659-25-005814
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves EBR Systems' WiSE CRT System for commercial distribution in US
---------------------------------------------------------------------------

- FDA approved WiSE CRT System for left ventricular endocardial pacing; target initial US addressable market ~$3.6B.
- Indicated for previously untreatable (failed CS lead) and high-risk upgrade patients aged ≥22.
- Limited market release in late 2025; full commercial launch expected early 2026.
- Post-approval study of 320 patients over 5 years required; NTAP/TPT reimbursement effective Oct 1, 2025.
- Contraindications include triple anticoagulant therapy and allergy to procedural agents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347123/000121465925005814/0001214659-25-005814-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347123/000121465925005814/e4132508k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-25-005814

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer